Eagle Pharma And AMRI Announce Agreement to Jointly Develop, Manufacture And Commercialize Parenteral Drug Products

WOODCLIFF LAKE, N.J. & ALBANY, N.Y.--(BUSINESS WIRE)--Eagle Pharmaceuticals (“Eagle” or the “Company”) (NASDAQ:EGRX) and AMRI (NASDAQ:AMRI) today announced that they have entered into an agreement to jointly develop and manufacture several select and complex parenteral drug products for registration and subsequent commercialization in the United States, which will significantly expand Eagle’s portfolio of existing products and product candidates targeting therapeutic areas including oncology, critical care and orphan diseases.